Search Within

Alison Michele Schram

Formats
  1. Journal Article (60)
  2. Meeting Abstract (59)
  3. Editorial (3)
  4. Review (3)
  5. Miscellaneous (2)
  6. Research Letter (1)
Groups
  1. Department of Medicine (128)
  2. Early Drug Development Service (128)
  3. Gynecologic Medicine Service (128)
  4. Hematology-Oncology Fellows (128)
  5. Solid Tumor Oncology Division (128)
  6. GSK Faculty (54)

More Groups

People
  1. David Hyman (49)
  2. Alexander Drilon (46)
  3. Michael Berger (24)
  4. Barry Taylor (16)
  5. Marc Ladanyi (16)
  6. Helen Won (14)

More People

Years
  1. 2025 (10)
  2. 2024 (18)
  3. 2023 (9)
  4. 2022 (16)
  5. 2021 (17)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (30)
  2. Annals of Oncology (13)
  3. Cancer Research (13)
  4. Cancer Discovery (9)
  5. JCO Precision Oncology (6)
  6. Clinical Cancer Research (5)

More Publications

Publishers
  1. American Society of Clinical Oncology (36)
  2. American Association for Cancer Research (30)
  3. Oxford University Press (14)
  4. Nature Publishing Group (12)
  5. Elsevier Inc. (8)
  6. American Medical Association (3)

More Publishers

Results (128)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers
    Meeting Abstract

    Schram, A. M.; Goto, K.; Kim, D. W.; Martin-Romano, P.; Ou, S. H. I.; O'Kane, G. M.; O'Reilly, E. M.; Umemoto, K.; Duruisseaux, M.; Neuzillet, C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Meeting Abstract

    Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Nacev, B. A.; Rosenbaum, E.; Thornton, K. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Mechanisms of acquired resistance to TRK inhibitors
    Meeting Abstract

    Harada, G.; Choudhury, N. J.; Schram, A. M.; Rosen, E.; Murciano-Goroff, Y. R.; Falcon, C. J.; Wilhelm, C.; Kaplanis, L. A.; Liu, D.; Chang, J. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)
    Meeting Abstract

    Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation
    Meeting Abstract

    Dumbrava, E. E.; Johnson, M. L.; Tolcher, A. W.; Shapiro, G.; Thompson, J. A.; El-Khoueiry, A. B.; Vandross, A. L.; Kummar, S.; Parikh, A. R.; Munster, P. N.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • The bi-steric mTORC1-selective inhibitor RMC-5552 in tumors with activation of mTOR signaling: Preclinical activity in combination with RAS(ON) inhibitors in RAS-addicted tumors, and initial clinical findings from a single agent phase 1/1b study
    Meeting Abstract

    Burris, H. A. 3rd; Ulahannan, S. V.; Haura, E. B.; Ou, S. H. I.; Capasso, A.; Munster, P. N.; Kitai, H.; Wang, Z.; Hayes, J.; Tao, L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies
    Journal Article

    Murciano-Goroff, Y. R.; Schram, A. M.; Rosen, E. Y.; Won, H.; Gong, Y.; Noronha, A. M.; Janjigian, Y. Y.; Stadler, Z. K.; Chang, J. C.; Yang, S. R.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor
    Meeting Abstract

    Schram, A.; Borad, M.; Sahai, V.; Kamath, S.; Kim, R.; Liao, C. Y. A.; Oh, D. Y.; Ponz-SarviseĢ, M.; Yachnin, J.; Shell, S. A.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors
    Journal Article

    Borazanci, E.; Schram, A. M.; Garralda, E.; Brana, I.; Vieito Villar, M.; Spreafico, A.; Oliva, M.; Lakhani, N. J.; Hoffman, K.; Hallett, R. M.; more...
    ESMO Open (2022)

    Fulltext@MSK | Save